Rockingstone Advisors LLC Acquires Shares of 88,325 Teva Pharmaceutical Industries Ltd. $TEVA

Rockingstone Advisors LLC acquired a new stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 88,325 shares of the company’s stock, valued at approximately $2,757,000.

A number of other institutional investors have also modified their holdings of the stock. Caprock Group LLC raised its stake in shares of Teva Pharmaceutical Industries by 3.8% during the 4th quarter. Caprock Group LLC now owns 146,416 shares of the company’s stock valued at $4,570,000 after buying an additional 5,320 shares during the last quarter. KLP Kapitalforvaltning AS raised its stake in shares of Teva Pharmaceutical Industries by 0.8% during the 4th quarter. KLP Kapitalforvaltning AS now owns 369,359 shares of the company’s stock valued at $11,528,000 after buying an additional 3,000 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. raised its stake in shares of Teva Pharmaceutical Industries by 14.8% during the 4th quarter. Migdal Insurance & Financial Holdings Ltd. now owns 37,402,212 shares of the company’s stock valued at $1,167,323,000 after buying an additional 4,820,000 shares during the last quarter. Evergreen Capital Management LLC purchased a new position in shares of Teva Pharmaceutical Industries during the 4th quarter valued at about $330,000. Finally, TD Waterhouse Canada Inc. raised its stake in shares of Teva Pharmaceutical Industries by 5.1% during the 4th quarter. TD Waterhouse Canada Inc. now owns 14,519 shares of the company’s stock valued at $453,000 after buying an additional 700 shares during the last quarter. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Trading Down 0.2%

TEVA stock opened at $31.23 on Thursday. The company has a current ratio of 1.04, a quick ratio of 0.80 and a debt-to-equity ratio of 1.89. Teva Pharmaceutical Industries Ltd. has a 12-month low of $14.16 and a 12-month high of $37.35. The stock has a market cap of $35.90 billion, a price-to-earnings ratio of 26.02, a PEG ratio of 2.74 and a beta of 0.76. The business’s 50-day moving average is $31.35 and its 200 day moving average is $28.87.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings data on Wednesday, January 28th. The company reported $0.96 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.65 by $0.31. Teva Pharmaceutical Industries had a return on equity of 46.28% and a net margin of 8.16%.The company had revenue of $4.71 billion for the quarter, compared to analysts’ expectations of $4.36 billion. During the same period in the previous year, the firm posted $0.71 EPS. Teva Pharmaceutical Industries’s revenue was up 11.4% compared to the same quarter last year. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. On average, sell-side analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.62 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Mark Sabag sold 62,102 shares of Teva Pharmaceutical Industries stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $30.14, for a total value of $1,871,754.28. Following the sale, the insider directly owned 224,940 shares in the company, valued at approximately $6,779,691.60. The trade was a 21.64% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Brian Savage sold 1,127 shares of Teva Pharmaceutical Industries stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $31.67, for a total value of $35,692.09. Following the completion of the sale, the insider owned 10,914 shares in the company, valued at approximately $345,646.38. The trade was a 9.36% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 920,901 shares of company stock worth $30,056,789 in the last quarter. 0.54% of the stock is owned by insiders.

Analyst Ratings Changes

A number of equities analysts have weighed in on TEVA shares. Bank of America lifted their price objective on Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday, April 9th. Jefferies Financial Group raised their target price on Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the company a “buy” rating in a research report on Tuesday, January 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research report on Monday. Truist Financial raised their target price on Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the company a “buy” rating in a research report on Wednesday, February 18th. Finally, Wall Street Zen upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 31st. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $38.78.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.